The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension

Medical Science Monitor

Volumn 10, Issue 2, 2004, Pages

  Czarnecka, Danuta ^a   Kawecka Jaszcz, Kalina ^a   Olszanecka, Agnieszka ^a   Dembińska Kieć, Aldona ^a   Malczewska Malec, Malgorzata ^a   Zdzienicka, Anna ^a   Guevara, Ibeth ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Endothelium; Hormone replacement therapy; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; NITRIC OXIDE; NITRITE; NORETHISTERONE ACETATE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

ADMINISTRATION, CUTANEOUS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHOLESTEROL, LDL; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTENSION; MIDDLE AGED; NITRIC OXIDE; NITRITES; NORETHINDRONE; POSTMENOPAUSE; TIME FACTORS;

EID: 1242330825     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rexrode KM, Manson JE, Lee IM et al: Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation, 2003; 108: 1688-93
2. Rossouw JE, Anderson GL, Prentice RL et al, Working Group for the Women's Health Initiative Investigators: Risk and benefits of oestrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288: 321-33
3. Scuteri A, Bos AJ, Brant LJ et al: Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med, 2001; 135: 229-34
4. Gilligan DM, Badar DM, Panza JA et al: Acute vascular effects of estrogen in postmenopausal women. Circulation, 1994; 90: 786-91
5. Lieberman EH, Gerhard MD, Uehata A et al: Estrogen, improves endothelium-dependent, flow mediated vasodilation in postmenopausal women. Ann Intern Med, 1994; 121; 936-41
6. Laudański K, Cudnoch-Jȩdrzejewska A: Effects of ovariectomy on the regulation of cardiovascular functions in female Wistar rats. Med Sci. Monit, 2001; 7: 1188-92
7. Herrington DM, Braden GA, Williams JK, Morgan TM: Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol, 1994; 73: 951-52
8. Reis SE, Gloth ST, Blumenthal RS et al: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women Circulation, 1994; 89: 52-60
9. Gilligan DM, Badar DM, Panza JA et al: Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol, 1995; 75: 264-68
10. Gryglewski R, Chlopicki S, Uracz W, Marcinkiewicz E: Significance of endothelial prostacyclin and nitric oxide in peripherial and pulmonary circulation. Med Sci Monit, 2001; 7: 1-16
11. Cicinelli E, Ignarro LJ, Lograno M et al: Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril, 1997; 67: 63-66
12. Binko J, Majewski H: 17 β-estradiol reduces vasoconstriction in endothelium denuded rat aortas through inducible NOS. Am J Physiol, 1998; 274: H853-59
13. Roque M, Heras M, Roig E et al: Short-term effects to transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol, 1998; 31: 139-43
14. Jokela H, Dastidar P, Rontu R et al: Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J Clin Endocrinol Metab, 2003; 88: 4348-54
15. Guevara I, Iwanejko J, Dembińska-Kieć A: Determination of nitrite/nitrate in human biological material by the sample Griess reaction. Clin Chim Acta, 1998; 274: 177-88
16. Lip GY, Beevers M, Churchill D, Beevers DG: Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens, 1994; 8: 491-94
17. Sumino H, Ichikawa S, Kamakura H et al: Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens. Res, 2003; 26: 369-76
18. Kornhauser C, Malacara JM, Garay ME, Perez-Luque EL: The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens, 1997; 11: 405-11
19. Manhem K, Ahlm M, Milsom I, Svensson A: Transdermal oestrogen reduces daytime blood pressure in hypertensive women. J Hum Hypertens, 1998; 12: 323-27
20. The writing group for PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA, 1995; 273: 199-208
21. Grady D, Herrington D, Bittner V et al: For the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS) JAMA, 2002; 288: 49-57
22. Carcia CE, Kilcoyne CM, Cardillo C et al: Effect of cooper-zinc superoxide dismutase on endothelium - dependent vasodilation in patients with essential hypertension. Hypertension, 1995; 26: 863-68
23. Linder L, Kiowski W, Buhler FR, Luscher TF: Indirect evidence for release of endothelium-derived relaxing factor in the human forearm circulation in vivo. Blunted response in essential hypertension. Circulation, 1990; 81: 1762-67
24. Panza JA, Casino PRC, Kilcoyne CM, Quyyumi AA: Impaired endothelium dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol, 1994; 23: 1610-16
25. Takahashi H, Nakanishi T, Nishimura M et al: Measurements of serum levels of nitrate ions in men and women: implications of endothelium-derived relaxing factor in blood pressure regulation and atherosclerosis. J Cardiovasc Pharmacol, 1992; 20(suppl 12): S214-S216
26. Sagnella GA, Markandu ND, Onipinla AK et al: Plasma and urinary nitrate in essential hypertension. J Hum Hypertens, 1997; 11: 587-88
27. Node K, Kitakaze M, Yoshikawa H et al: Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension, 1997; 30: 405-08
28. Imthurn B, Rosselli M, Jaeger AW et al: Differential effects of hormone replacement therapy on endogenous nitric oxide levels in postmenopausal women substituted with 17 β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab, 1997; 82: 388-94
29. Best PJM, Berger PB, Miller VM, Lerman A: The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med, 1998; 128: 285-88
30. Ramsay B, Johnson MR, Leone AM, Steer PJ: The effect of exogenous oestrogen on nitric oxide production in women: a placebo controlled crossover study. Br J Obstet Gynaecol, 1995; 102: 417-19
31. Losordo DW, Kearney M, Kim EA et al: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation, 1994; 89: 1501-10
32. Stefano G, Peter D: Cell surface estrogen receptors coupled to cNOS mediate immune and vascular tissue regulation: therapeutic implications. Med Sci Monit, 2001; 7: 1066-74
33. Rosser M, Chorich L, Howard E et al: Changes in rat uterine estrogen receptor messenger ribonucleic acid levels during estrogen and progesterone induced estrogen receptor depletion and subsequent replenishment. Biol Reprod, 1993; 48: 89-98
34. Lobo RA: The role of progestins in hormone replacement therapy. Am J Obstet Gynecol, 1992; 166: 1997-2004
35. Wolinsky H: Effects of estrogen and progesterone treatment on the response of the aorta ofmale rats to hypertension. Morphological and chemical studies. Circ Res, 1972; 30: 341-49
36. Rosselli M, Imthurn B, Keller PJ et al: Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension, 1995; 25(4 Pt 2): 848-53
37. Nabulsi AA, Folsom AR, White A et al: Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med, 1993; 328: 1069-75
38. Best PJM, Berger PB, Miller VM, Lerman A: The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med, 1998; 128: 285-88
39. Anggard E: Nitric oxide: mediator, murderer and medicine. Lancet, 1994; 343: 1199-206
40. Azuma H, Sato J, Hamasaki H et al: Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol, 1995; 115: 1001-04
41. Hibbs JP, Westenfelder C, Taintor R et al: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest, 1992; 89: 867-77
42. Jungersten L, Edlund A, Petersson AS, Wennmalm A: Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol, 1996; 16: 369-79
43. Dusting GJ: Nitric oxide in cardiovascular disorders. J Vasc Res, 1995; 32: 143-61
44. Cadwgan TM, Benjamin N: Evidence of altered platelet NO synthesis in essential hypertension. J Hypertens, 1993; 11: 417-20
45. Zhou Q, Hellermann GR, Solomonson LP: Nitric oxide release from resting human platelets. Thromb Res, 1995; 77: 87-96